Sign In
Buy CRBP
$7.38
-0.160 (-2.12%)
At Close: Jun 03, 2026
Bank of New York Mellon Corp Acquires 4,025 Shares of Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP)
08:20am, Saturday, 25'th Apr 2020
Bank of New York Mellon Corp raised its stake in Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) by 2.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and
Cannabis Central: Sector Was Up On Wednesday But Is Down 42.5% YTD
08:49am, Thursday, 23'rd Apr 2020
The Non-penny Pot Stock Index tracks the 35 pot stocks that trade for +US$1/share. It was - 0.3% on Wednesday but is +6.9% so far in April (-19% YTD). The entire sector was +1.1% today but is -4.8% so
Oppenheimer Remains a Buy on Urogen Pharma (URGN)
04:25am, Tuesday, 21'st Apr 2020
In a report released today, Leland Gershell from Oppenheimer maintained a Buy rating on Urogen Pharma (URGN), with a price target of $47.00. The company's
Oppenheimer Remains a Buy on Urogen Pharma (URGN)
04:25am, Tuesday, 21'st Apr 2020
In a report released today, Leland Gershell from Oppenheimer maintained a Buy rating on Urogen Pharma (URGN – Research Report),
Ascendis Pharma (ASND) Received its Third Buy in a Row
11:24am, Monday, 20'th Apr 2020
After Merrill Lynch and Canaccord Genuity gave Ascendis Pharma (NASDAQ: ASND) a Buy rating last month, the company received another Buy, this time from
Ascendis Pharma (ASND) Received its Third Buy in a Row
11:24am, Monday, 20'th Apr 2020
After Merrill Lynch and Canaccord Genuity gave Ascendis Pharma (NASDAQ: ASND) a Buy rating last month, the company received another
3 Reasons Medical Marijuana Is a Better Long-Term Investment Than Recreational Pot
11:45am, Sunday, 19'th Apr 2020
Not all pot stocks are wildly volatile, and there are safer options out there for cannabis investors.
Urogen Pharma (URGN) Received its Third Buy in a Row
04:07am, Friday, 17'th Apr 2020
After H.C. Wainwright and Stifel Nicolaus gave Urogen Pharma (NASDAQ: URGN) a Buy rating last month, the company received another Buy, this time from
Urogen Pharma (URGN) Received its Third Buy in a Row
04:07am, Friday, 17'th Apr 2020
After H.C. Wainwright and Stifel Nicolaus gave Urogen Pharma (NASDAQ:
URGN
) a Buy rating last month, the company received another Buy, this time from Oppenheimer. Analyst
Leland Gershell
maintained a
RemeGen candidate Fast Track'd for lupus
03:13pm, Wednesday, 15'th Apr 2020
The FDA has signed off on Fast Track status for Yantai, China-based RemeGen's lead drug RC18 for the treatment of systemic lupus erythematosus (SLE).RC18 (telitacicept) is a recombinant TACI-F
Corbus Pharmaceuticals (NASDAQ:CRBP) Trading Up 0.3%
11:06am, Wednesday, 15'th Apr 2020
Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) shares were up 0.3% on Monday . The company traded as high as $5.75 and last traded at $5.77, approximately 530,737 shares traded hands during mid-day
Corbus Pharmaceuticals (NASDAQ:CRBP) Upgraded to "Buy" by BidaskClub
07:44am, Wednesday, 15'th Apr 2020
Corbus Pharmaceuticals (NASDAQ:CRBP) was upgraded by investment analysts at BidaskClub from a “hold” rating to a “buy” rating in a research report issued on Wednesday, BidAskClub reports. Seve
ESPAOL • Empresas de Cannabis con Acciones el NYSE y NASDAQ: Una Lista Completa
05:47pm, Tuesday, 14'th Apr 2020
Articulo via El Planteo.Mientras la industria del cannabis sigue avanzando, mas y mas compañias se mueven para conseguir que sus acciones esten en las listas de las bolsas de valores estadounidenses
Oppenheimer Remains a Hold on Amarin (AMRN)
03:35am, Tuesday, 14'th Apr 2020
Oppenheimer analyst Leland Gershell maintained a Hold rating on Amarin (AMRN) yesterday. The company's shares closed last Monday at $6.39, close to its
Oppenheimer Remains a Hold on Amarin (AMRN)
03:35am, Tuesday, 14'th Apr 2020
Oppenheimer analyst
Leland Gershell
maintained a
Hold
rating on Amarin (
AMRN
–
Research Report
) yesterday. The company’s shares closed last Monday at $6.39, close to its 52-week low of $3.96.
Ac
